DJIA 17,630.64 -99.47 -0.56%
NASDAQ 4,971.51 -37.71 -0.75%
S&P 500 2,060.55 -16.23 -0.78%
market minute promo

Seattle Genetics (NASDAQ: SGEN)

47.32 -0.33 (-0.69%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

SGEN $47.32 -0.69%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $47.27
Previous Close $47.65
Daily Range $46.61 - $48.65
52-Week Range $30.05 - $49.84
Market Cap $5.9B
P/E Ratio -72.20
Dividend (Yield) $0.00 (0.0%)
Volume 604,025
Average Daily Volume 838,534
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drug Makers

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

News & Commentary Rss Feed

Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?

Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.

How To Make Money In Small To Nano-Cap Biotech

Interesting SGEN Put And Call Options For August 21st

Seattle Genetics' Collaborative Approach To Fighting Cancer Makes It A Buy

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the Intern

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutic

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases

Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog

3 Stocks Improving Performance Of The Drugs Industry

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

Seattle Genetics Larger Than S&P 500 Component Tenet Healthcare

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Program

Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs

See More SGEN News...

SGEN's Top Competitors

SGEN $47.32 (-0.69%)
Current stock: SGEN
AMGN $153.94 (0.44%)
Current stock: AMGN
GILD $115.18 (0.12%)
Current stock: GILD
BIIB $403.35 (-0.23%)
Current stock: BIIB